Weekly injection study for children with achondroplasia
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.
This trial looks at how safe and effective weekly under-the-skin (subcutaneous) TransCon CNP is for children and teens with achondroplasia over the long term. You may be considered if your child has already finished a previous TransCon CNP study and can follow weekly injection and follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your parent/legal guardian can give consent, and your child can assent if required by age rules
- You previously completed an earlier clinical trial with TransCon CNP
- A parent/guardian can give weekly under-the-skin injections and follow the study schedule
- You do not have a known allergy or serious reaction to TransCon CNP ingredients (including trehalose, specific buffer salts, or mPEG)
- If you take part in the study, you must avoid other prescription or study medicines (except TransCon CNP) during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This study tests an oral medicine (ABSK061) to see if it can safely improve growth in children with achondroplasia. It is a phase 1/2 trial, meaning it is early research to find the right dose and check for benefits.
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
This study tests an experimental oral medication (TYRA-300) for children with achondroplasia, a common form of dwarfism. The goal is to see if it can safely improve growth in children whose growth plates are still open.
This study is tracking how people with achondroplasia or hypochondroplasia move their limbs in daily life using a small wearable device. The information will help doctors better understand these conditions and may lead to better care.
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.